Erste Group downgraded Vertex Pharmaceuticals (VRTX) to Hold from Buy. The company’s ratio of inventories to sales has reached its highest level in the last 10 years, which is currently having a negative impact, the analyst tells investors in a research note. The firm says Vertex’s ratio of receivables to sales is also at a very high level.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals Launches $4 Billion Stock Buyback
- Vertex Pharmaceuticals: Strategic Positioning and Promising Growth Prospects Underpin Buy Rating
- Vertex Pharmaceuticals Holds Annual Shareholder Meeting
- Vertex Pharmaceuticals: Strong Growth and Promising Pipeline Justify Buy Rating
- Skechers, Shopify, Diamondback, Vertex, Turtle Beach: Trending by Analysts